Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 2.72 g/t Au over 139.9 metres at Golden Summit (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News PaxMedica Inc PXMD

Healthcare Biotechnology
PaxMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to neurodegenerative disorders, such as Fragile X Tremor Ataxia Syndrome (FXTAS) and post-viral... see more

Recent & Breaking News (GREY:PXMD)

PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions

Accesswire 7 days ago

PaxMedica Secures Immediate Exercise of Warrants

Accesswire September 3, 2024

PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection

Accesswire August 27, 2024

PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101

GlobeNewswire May 15, 2024

PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy

GlobeNewswire May 7, 2024

PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101

GlobeNewswire April 23, 2024

PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness

GlobeNewswire April 16, 2024

PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission

GlobeNewswire April 11, 2024

PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments

GlobeNewswire March 13, 2024

PaxMedica Releases Fireside Chat Video with CEO Howard Weisman

Accesswire December 6, 2023

PaxMedica Announces Closing of $7.0 Million Public Offering

Accesswire November 22, 2023

PaxMedica Announces Pricing of $7.0 Million Public Offering

Accesswire November 20, 2023

PaxMedica Inc. Featured in Syndicated Broadcast Highlighting FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data

GlobeNewswire November 17, 2023

PaxMedica, Inc. Announces Third Quarter 2023 Financial Results and Business Update

Accesswire November 15, 2023

PaxMedica Announces Publication of Its Autism Spectrum Disorder Phase 2 Study Results in Peer-reviewed Journal

Accesswire November 7, 2023

PaxMedica Engages Bourne Partners to Explore Future Monetization of Potential Priority Review Voucher (PRV)

GlobeNewswire November 2, 2023

PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101

GlobeNewswire October 31, 2023

PaxMedica Announces 1-for-17 Reverse Stock Split

GlobeNewswire October 30, 2023

PaxMedica's Research on Low Dose Suramin for Autism Spectrum Disorder Accepted for Publication

GlobeNewswire October 26, 2023

PaxMedica Holds Important FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data

Accesswire October 26, 2023